Trial Profile
To Evaluate Effectiveness of Aclidinium Bromide/Formoterol Fumarate Dihydrate in Chronic Obstructive Pulmonary Disease
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Aclidinium bromide/formoterol (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms ASTUTE
- Sponsors AstraZeneca
- 30 Jun 2017 Planned End Date changed from 24 Aug 2018 to 3 Dec 2018.
- 30 Jun 2017 Planned primary completion date changed from 24 Aug 2018 to 3 Dec 2018.
- 30 Jun 2017 Planned initiation date changed from 25 Aug 2017 to 4 Dec 2017.